A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes

Diabetes, Obesity and Metabolism

Volumn 13, Issue 9, 2011, Pages 806-813

  Kong, A P S ^a   Yamasaki, A ^b   Ozaki, R ^a   Saito, H ^b   Asami, T ^b   Ohwada, S ^b   Ko, G T C ^a,c   Wong, C K ^a   Leung, G T C ^a   Lee, K F ^d   Yeung, C Y ^e   Chan, J C N ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b DAIICHI SANKYO CO   (Japan)

^c ALICE HO MIU LING NETHERSOLE HOSPITAL   (Hong Kong)

^d KWONG WAH HOSPITAL   (Hong Kong)

^e PAMELA YOUDE NETHERSOLE EASTERN HOSPITAL   (Hong Kong)

Author keywords

PPAR gamma agonist; Rivoglitazone; Thiazolidinediones; Type 2 diabetes

Indexed keywords

ADIPONECTIN; C PEPTIDE; C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; PLACEBO; RIVOGLITAZONE; TRIACYLGLYCEROL;

ABDOMINAL DISCOMFORT; ARTHRALGIA; ARTICLE; BACKACHE; BLURRED VISION; CHINESE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; COUGHING; CREATINE KINASE BLOOD LEVEL; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE DURATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DRY SKIN; DYSPNEA; EDEMA; FEMALE; GASTROENTERITIS; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART PALPITATION; HEMATURIA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; INSULIN BLOOD LEVEL; LETHARGY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MULTICENTER STUDY; MUSCLE SPASM; MUSCULOSKELETAL PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL EDEMA; POSITIONAL DIZZINESS; PROTEIN BLOOD LEVEL; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT WITHDRAWAL; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION;

EID: 79960815783     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01411.x     Document Type: Article

References (16)

1. Tzoulaki I, Molokhia M, Curcin V et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009; 339: b4731.
2. Henry RR. Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes. Clin Ther 2003; 25: B47-B63.
3. Kaul S, Bolger AF, Herrington D, Giugliano RP, Eckel RH. Thiazolidinedione drugs and cardiovascular risks. A science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation 2010; 121: 1868-1877.
4. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
5. Nissen SE. The rise and fall of rosiglitazone. Eur Heart J 2010; 31: 773-776.
6. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone clinical trial in macrovascular events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
7. Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373: 2125-2135.
8. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
9. Yamanouchi T. Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes. J Vasc Health Risk Manag 2010; 6: 189-197.
10. Monami M, Lamanna C, Marchionni N, Mannucci E. Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care 2008; 31: 1455-1460.
11. Yang X, Ko GT, So WY et al. Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry. Diabetes 2010; 59: 1254-1260.
12. Kanda S, Nakashima R, Takahashi K et al. Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, in obese diabetic rodent models. J Pharmacol Sci 2009; 111: 155-166.
13. Rohatagi S, Carrothers TJ, Jin J et al. Model-based development of a PPARgamma agonist, rivoglitazone, to aid dose selection and optimize clinical trial designs. J Clin Pharmacol 2008; 48: 1420-1429.
14. Leung TK, Luk AO, So WY, Lo MK, Chan JC. Development and validation of equations estimating glomerular filtration rates in Chinese patients with type 2 diabetes. Kidney Int 2010; 77: 729-735.
15. Mathews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and ß cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
16. Chan JC, Malik V, Jia W et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009; 301: 2129-2140.